Correlations of bcl-2 expression with clinicopathological features in breast cancer
Yonsei Medical Journal
;
: 206-211, 1997.
Article
Dans Anglais
| WPRIM
| ID: wpr-70663
ABSTRACT
To evaluate the prognostic significance of bcl-2, we investigated the correlation of bcl-2 expression with the established indicators of prognosis and tumor behavior in breast cancer. This study included a patient group of 91 histologically diagnosed female breast carcinomas. To determine the bcl-2 immunoreactivity, we used a monoclonal antibody directed against the bcl-2 protein by immunohistochemistry from paraffin-embedded tissue in a series of 91 women with breast cancer. Interpretable DNA histograms were obtained from 84 patients. The median age at diagnosis was 45.5 years and the median follow-up time was 30.5 months. Forty-eight (52.7%) cancers showed the bcl-2 immunoreactivity in the cytoplasm. The nonneoplastic portion of ductal epithelial cells and normal lymphocytes were usually stained with bcl-2 antibody. Estrogen receptors (ER)(p 0.05) and DNA ploidy (p > 0.05) were not related with it. The bcl-2 positive patients showed longer survival (p 0.05), nuclear grade (p > 0.05), ER status (p > 0.1) and PR status(p > 0.1) were not reliable indicators for overall survival except histologic grade (p < 0.05). Our results suggest that bcl-2 expression may be related to hormonal regulation and tumor differentiation in breast carcinoma. Larger patient study groups with a longer follow-up period will be helpful to clarify the prognostic significance of bcl-2.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs du sein
/
Épithélioma in situ
/
Récepteurs à la progestérone
/
Récepteurs des oestrogènes
/
Carcinome canalaire du sein
/
Protéines proto-oncogènes c-bcl-2
/
Adulte d'âge moyen
Limites du sujet:
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Yonsei Medical Journal
Année:
1997
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS